Phase I clinical trial outcome shows Covaxin generates antibody, T-cell memory response
we hypothesize that BBV152 can generate antibodies that may persist for 6-12 months.
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.